The fact that ALDH2*2 mutation is a double edged sword that increases both susceptibility to certain upper respiratory tract/esophageal cancers and can also limit the amount of cisplatin, may be useful information in the context of cisplatin treatment. This evidence concerns the gene ALDH2 and esophageal cancer.